|
|
1.
|
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. MedStar authors:
Year: 2024
Citation: - Journal of Clinical Oncology. 42(11):1288-1300, 2024 Apr 10.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
All authors: - Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ
|
|
|
2.
|
Ten-year Update: NRG Oncology/NSABP B-42 Randomized Trial: Extended Letrozole Therapy in Early-stage Breast Cancer. MedStar authors:
- McCarron, Edward C
- Swain, Sandra M
Year: 2023
Citation: - Journal of the National Cancer Institute. 2023 May 15
Institution:
- Associate Dean for Research Development
- MedStar Franklin Square Medical Center
- MedStar Health
Medline publication type:
All authors: - Bandos H, Brufsky AM, Chia SK, Dakhil SR, Fehrenbacher L, Geyer CE, Jeong JH, Lembersky BC, Mamounas EP, McCarron EC, Rastogi P, Soori GS, Swain SM, Wade JL, Walshe JM, Wolmark N
|
